RT Journal Article
T1 Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients.
A1 Loucera, Carlos
A1 Peña-Chilet, María
A1 Esteban-Medina, Marina
A1 Muñoyerro-Muñiz, Dolores
A1 Villegas, Román
A1 Lopez-Miranda, Jose
A1 Rodriguez-Baño, Jesus
A1 Túnez, Isaac
A1 Bouillon, Roger
A1 Dopazo, Joaquin
A1 Quesada Gomez, Jose Manuel
AB COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15-30 days before hospitalization were recorded. The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan-Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50-0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61-0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57-0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization.
YR 2021
FD 2021-12-03
LK https://hdl.handle.net/10668/25513
UL https://hdl.handle.net/10668/25513
LA en
DS RISalud
RD Apr 11, 2025